A gel-like or cloudy preparation should not be declared safe solely because someone says that gelling is common. Appearance cannot establish its cause, the remaining amount of intended material or suitability for administration.
Aggregation is a quality question
The FDA's AOD-9604 chemistry assessment discusses sensitivity to formulation, manufacturing and storage conditions. It identifies aggregation and peptide-related impurities as important concerns.
That does not mean every visible change has the same mechanism. It means that a generic reassurance is insufficient. A photograph or customer-service explanation cannot substitute for evidence about the particular preparation.
Physical change does not settle clinical risk
A statement that a change is physical rather than chemical is not a complete safety argument. Product performance, distribution of material and immune-related concerns can still require assessment.
Conversely, this article cannot identify contamination or a specific defect from a Reddit account. The correct response is to preserve the uncertainty rather than diagnose the vial by appearance.
A clear preparation is not automatically suitable either. Important quality failures may not be visible.
Do not improvise a rescue procedure
Online suggestions to change acidity, add another liquid, heat, filter or otherwise manipulate a preparation do not establish that it becomes an acceptable product. This article provides no method for rescuing or administering altered research material.
If the product was legitimately prescribed, contact the dispensing pharmacist or prescriber and follow their product-specific instructions. Retain the label, lot information, photographs and handling history for that discussion.
For research-only material, a seller's statement that a texture is expected does not establish medical suitability. A certificate also needs to match the actual sample and relevant quality questions.
The practical point is simple: normal-looking, commonly reported and scientifically acceptable are different claims. AOD-9604's known formulation challenges are a reason for more careful characterization, not a reason to treat visible changes as harmless without evidence.